Jacob Wackerhausen/iStock via Getty Images Incyte Corporation (NASDAQ:INCY) has been able to achieve several key milestones over the past year, many of which, I believe, could drive shareholder growth. On one front, I believe that this company could be in a position to grow its Monjuvi drug franchise. Why is that? That's because this CD19 targeting monoclonal antibody in combination with lenalidomide was given Accelerated Approval by the FDA and Conditional Marketing Authorization by the European Medicines ...

Incyte (INCY) announced that the late-stage inMIND study on tafasitamab met its primary and secondary endpoints. This phase III study is evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with Revlimid and Rituxan compared to Revlimid and Rituxan alone in patients with relapsed or refractory follicular lymphoma (FL). The trial met its primary endpoint of progression free survival (PFS) by investigator assessment ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (State or ...

Incyte Corporation (NASDAQ:INCY) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Barry Flannelly - General Manager, North America Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Kripa ...

Incyte Corporation (INCY) reported second-quarter 2024 adjusted loss of $1.82 per share against the Zacks Consensus Estimate of earnings of 78 cents. The company had recorded earnings of 99 cents per share in the year-ago quarter. Quarter in Detail Opzelura (ruxolitinib) cream generated $121.7 million in sales, which rose 52% year over year and surpassed the Zacks Consensus Estimate of $114 million. The year-over-year rise in sales was driven by patient demand, refills and expansion in payer coverage in bot ...

This quarterly report represents an earnings surprise of -333.33%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.88 per share when it actually produced earnings of $0.64, delivering a surprise of -27.27%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. While Incyte has underperformed the market so far this year, the qu ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,044 million in the second quarter (Q2'24) (+9% Y/Y) – Jakafi (ruxolitinib) net product revenues of $706 million in Q2'24 (+3% Y/Y), total patients increased +7% Y/Y; raising the bottom end of full year 2024 guidance to a new range of $2,710 - $2,750 million ® – Opzelura (ruxolitinib) net product revenues of $122 million in Q2'24 (+52% Y/Y); continued up ...

We expect Incyte Corporation (INCY) to surpass expectations when it reports second-quarter 2024 results on Jul 30, before the opening bell. Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs. Incyte earns product royalty revenues from Novartis AG (NVS) for the commercialization of Jakafi in ex-U.S. markets. Novartis licensed ruxolitinib for its development and commercialization outside the United States. Incyte also ...

Incyte (INCY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. This specialty drugmaker is expected to post quarterly earnings of $1.16 per share in its upcoming report, which represents a year-over-year change of ...

Right now, Incyte is sporting a Zacks Rank of #2 (Buy), while Myriad Genetics has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that INCY is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors. INCY currently has a forward P/E ratio of 14.82, while MYGN has a forward P/E of 824.48. We also note that INCY has a PEG ...